In one breast cancer study, OSBPL10 mutations, which have a prevalence of 5.2%, have been suggested as potential drivers of mutations; however, the clinical impacts of OSBPL10 mutations were not described [35]. This evidence concerns the gene OSBPL10 and breast cancer.